SILVER LINK的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到附近那裡買和營業時間的推薦產品

隱喻領導力：啟發洞見、解決難題的200則思考提醒

為了解決SILVER LINK的問題，作者彼得•蕭 這樣論述：

　　隱喻是一個強而有力的交流工具， 　　一個隱喻可能勝過千言萬語，節省大量的表達用詞。 　　隱喻能創造想像空間，讓人重新思考問題， 　　從而開闢全新解決方案的可能性。   　　身為職場領導者或工作者，善用隱喻可以激勵員工或同事採取行動及產生改變。 　　隱喻不僅使溝通有成效，還能讓人迅速認清現實， 　　脫離無效目標，重新開始或改變方向。 　　隱喻更可用於對話指導，激發想像力和啟發對話。 　　舉例來說： 　　「The Emperor’s new clothes.」（國王的新衣：安徒生童話裡的國王一絲不掛遊街，是因為沒有人敢說出真相。） 　　──太多領導者總是偏聽他人的曲意奉承

，看不清事情的真相。 　　思考提示：面對生活，需要足夠的勇氣與無私的坦然，才能發現真理。 　　「The elephant in the room.」(房間裡的大象：房間裡明明有隻大象，人們卻當作沒看見。) 　　──有時候問題過於難解，但是它明明還在，人們就是得過且過或絕口不提。 　　思考提示：你不批評、不指責，單純就事論事，以開放的態度討論解決方案。 　　「Face the music .」(勇於面對現實，接受不好的後果：這裡不是要你面對音樂，而是要你承擔做錯事的後果。) 　　──判斷錯誤，就要自己承擔後果。 　　思考提示：眼看著事態發展不如預期，你有多大的心胸願意負起責任？ 　　「Pu

t a tiger in your tank.」(油箱裡的猛虎能量：在你的油箱裡放一隻老虎？！這是知名汽油品牌ESSO的廣告文案，但老虎與汽油有什麼關係呢？正是這種隱喻，使人想去探究其深層的含義：這種汽油將為你的汽車帶來無限的動力，猶如一頭猛虎。) 　　──有時候你需要將精力集中在某個能讓你不遺餘力的目標。 　　思考提示：你的抗壓性高嗎？假如遇到必須迅速執行的活動，你會有什麼風險？ 　　「Act the goat.」(裝瘋賣傻／幹盡蠢事：這可不是扮一隻山羊，這是為了逃避責任的「裝傻」，也可解釋為逗人一笑的「耍笨」，有時候還可形容「瘋癲」。) 　　──有時候我們會做一些別人眼中的蠢事而不自知。

　　思考提示：你願不願意基於好理由讓自己顯得有點愚蠢？因為這樣能夠累積相當程度的好感。 　　寥寥數語的「隱喻」濃縮了集體經驗的智慧。 　　利用「隱喻」思考問題，有助於解放思路，開啟更多新的解決方案。 　　藉由「隱喻」，我們能夠切中問題核心、釐清事態、帶來洞見，或者指出癥結所在。 　　本書收錄200則多樣化的「隱喻」，有些很新穎，有些早已膾炙人口， 　　每一則都值得我們玩味；而且可供領導者在不同的環境下應用。 　　領導者在各式各樣的情況下思考如何表現出最佳引導和影響力， 　　本書可作為豐富的思考提示資源。 　　請讓想像力隨著每一則隱喻共舞，展開新洞見的種種可能， 　　人生將會處處充滿驚喜，

而且讓人樂在其中。  

SILVER LINK進入發燒排行的影片

無氟超疏水高分子複合材料製備及其在高效能油水分離與乳化液分離之應用

為了解決SILVER LINK的問題，作者Dula Daksa Ejeta 這樣論述：

在工業上以及我們的日常生活中常會產生許多含油廢水，這些含油廢水的排放以及海面上的漏油汙染皆會對自然環境造成嚴重的影響。此外，在石油化學工業中，油品中的少量水分也會對其造成許多問題，這些問題需耗費許多資源來解決。因此，開發具有高通量、低耗能、操作簡易、低成本、可量產之乳化劑穩定油包水乳化液處理材料是一個重要的課題。在本研究分為三個部分，我們製備三種具有不含氟、價格低廉之超疏水高分子複合材料。第一個研究中，我們利用聚（4-乙基苯酚）與1,3-phenylene bisoxazoline改質市售棉花，製備具有超疏水與超親油特性之高分子複合材料。此材料經壓縮後可應用於油包水乳化液分離，在重力過濾與加

壓過濾下可分別展現10,400 L m-2 h-1 (gravity-driven) and 867,500 L m-2 h-1 bar-1 (0.1 bar)的高通量。在第二個研究中，我們以主練型聚氧代氮代苯并環己烷改質美耐皿海綿製備超疏水材料，此材料展現極佳的吸油特性(最多可吸附本身重量170倍之油汙)，壓縮後可應用於油包水乳化液分離，在重力過濾與加壓過濾下可分別展現13,900 L m-2 h-1 (gravity-driven) and 1,353,000 L m-2 h-1 bar-1 (0.025 bar)的高通量。最後一個研究中，我們利用酚醛樹脂與氧代氮代苯并環己烷改質市售棉花，

製備超疏水高分子複合材料。此材料可應用於油水混和液分離，展現1.8x105 L m-2 h-1的高通量。壓縮後可應用於油包水乳化液分離，展現1.6x106 L m-2 h-1 bar-1 (0.025 bar)的高通量。以上的乳化液分離實驗中，濾液的油純度皆高於99.95 wt%，分離效果良好。我們的超疏水高分子複合材料因其高通量、高分離效率、低成本的製備方法皆說明它們在現實應用中具有巨大的潛力。

Current Issues in Medicine: Immunology, Microbiology, Biostatistics, and Big Data

為了解決SILVER LINK的問題，作者Bawa, Raj,Szebeni, Janos,Dobrovolskaia, Marina A. 這樣論述：

Raj Bawa, MS, PhD, is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, Virginia, USA, that he founded in 2002. Trained as a biochemist and microbiologist, he is an inventor, entrepreneur, professor, and registered patent agent licensed to practice bef

ore the US Patent & Trademark Office. He is currently a scientific advisor to Teva Pharmaceutical Industries, Ltd. (Israel), a visiting research scholar at the Pharmaceutical Research Institute of Albany College of Pharmacy (Albany, New York), and vice president and chief intellectual property offic

er at Guanine, Inc. (Rensselaer, New York). He has previously served as a principal investigator of National Cancer Institute SBIRs and continues to be a scientific reviewer for both the NIH and NSF. He recently (2017-2019) served as principal investigator of a CDC grant to develop an assay for Carb

apenem-resistant Enterobacteriaceae. Since 2004, he has been an adjunct professor in the biology department and the Extended Learning Institute of Northern Virginia Community College (Annandale, Virginia), where he also teaches human anatomy and physiology to pre-nursing students. In the 1990s, Dr.

Bawa held various positions at the US Patent & Trademark Office, including primary patent examiner from 1996-2002. Previously, he was an adjunct professor at Rensselaer Polytechnic Institute in Troy, New York from 1998-2018, where he received his doctoral degree in three years (biophysics/biochemist

ry). Dr. Bawa is a life member of Sigma Xi, co-chair of the nanotech and precision medicine committees of the American Bar Association (2015-2021), and founding director of the American Society for Nanomedicine (founded in 2008). He has authored over 100 publications, co-edited 9 texts, and serves o

n the editorial boards of numerous peer-reviewed journals, including serving as an associate editor of Nanomedicine (Elsevier). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, UK (2008); Appreciation Award from the US Undersecretary of Commerce,

Washington, DC (2001); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).Janos Szebeni, MD, PhD, DSc, is director of the Nanomedicine Research and Education Center at Semmelweis University in Budapest,

Hungary. He is also the founder and CEO of a contract research SME, SeroScience, Ltd., and a full professor of immunology and biology at the University of Miskolc in Hungary. He has held various academic positions in Hungary and abroad, including at the National Institute of Hematology and Blood Tra

nsfusion and at the First Clinics of Internal Medicine, Semmelweis University in Budapest, the University of Arizona in Tucson, AZ, the National Institute of Health in Bethesda, Maryland, Massachusetts General Hospital, Harvard University in Boston, MA, the Walter Reed Army Institute of Research in

Silver Spring, Maryland. After residing in the United States for over two decades, Dr. Szebeni returned to Hungary in 2006. His research on various themes in hematology, membrane biology, nanotechnology, and immunology has produced 160+ peer-reviewed papers, book chapters, patents, etc. (citations:

≈6000, H index: 39), and a book titled The Complement System: Novel Roles in Health and Disease (Kluwer, 2004). He has made significant contributions to three fields: artificial blood, liposomes, and the complement system. His original works led to the ＂CARPA＂ concept, i.e., that complement activati

on underlies numerous drug-induced (pseudo) allergic (infusion) reactions. Marina A. Dobrovolskaia, PhD, MBA, PMP, is laboratory director of operations and the head of the Immunology Section at the Nanotechnology Characterization Laboratory (NCL). In her role as the director of operations, she leads

the NCL operations to provide preclinical nanoparticle characterization services to the nanotechnology research community, advance the translation of promising nanotechnology concepts from bench to the clinic, and contribute to the education of the next generation of scientists in the field of prec

linical development of nanotechnology-based products, the activities emphasized in the NCL mission. She also directs the performance of Immunology, Client Relations and Administrative sections of the NCL. Closely integrated functioning of these sections plays a critical role in advancing the NCL’s k

ey strategic goals, and in supporting the missions of the Frederick National Laboratory for Cancer Research. In her role as the Head of the Immunology Section, Dr. Dobrovolskaia leads a team conducting preclinical studies to monitor nanoparticles’ toxicity to the immune system both in vitro and in v

ivo using variety of immune function animal models. Prior to joining the NCL, Dr. Dobrovolskaia worked as a Research Scientist in a GLP laboratory at PPD Development, Inc. in Richmond, VA, where she was responsible for the design, development and validation of bioanalytical ligand-binding assays to

support pharmacokinetic and toxicity studies in a variety of drug development projects. She received her M.S. degree from the Kazan State University in Russia; Ph.D. from the N.N. Blokhin Cancer Research Center of the Russian Academy of Medical Sciences in Moscow, Russia; and MBA from the Hood Colle

ge in Frederick, MD. Since 2016, she is also a member of Project Management Institute and a certified Project Management Professional. Her research interests include immunology, toxicology, nanotechnology and bioanalytical methodology. Dr. Dobrovolskaia’s list of publications and citations of the pu

blished work can be accessed via the following link https: //scholar.google.com/citations?user=Biz76XAAAAAJ&hl=en.Gerald F. Audette, PhD, is associate dean of faculty in the Faculty of Science, an associate professor of chemistry, and member of the Centre for Research on Biomolecular Interactions at

York University, Canada. His research focuses on the correlation between protein structure and biological activity of proteins involved in bacterial conjugation, in particular, the type 4 secretion system from the conjugative F-plasmid of Escherichia coli. In addition, his research targets the type

IV pilins and associated assembly systems from several bacterial pathogens and is exploring the adaptation of these protein systems for applications in bionanotechnology and nanomedicine. Dr. Audette is the co-editor of volumes 1-4 of the Jenny Stanford Series on Nanomedicine and is a subject edito

r of structural chemistry and crystallography for the journal FACETS.Brian E. Reese, PhD, JD, MBA, is a principal at Choate Hall & Stewart in Boston. He has extensive experience in intellectual property (IP) law, as well as IP-related transactional matters, including licensing and long-term developm

ent and collaboration matters. Dr. Reese primarily practices in the life sciences sector, and his combination of technical, legal, and business expertise allow him to provide unusually comprehensive and pragmatic strategic counsel to his practice. As a former stock analyst, Dr. Reese has a strong ap

preciation for the business realities his clients face as well as how IP and corporate transactions can help them achieve their objectives. Dr. Reese graduated with a BS in cellular biochemistry from the State University of New York at Plattsburgh. He subsequently obtained his PhD from the Pennsylva

nia State University for his research in the areas of neuroscience, molecular biology and toxicology, while also completing his MBA at Penn State. Dr. Reese attended Albany Law School in Albany, NY and graduated magna cum laude. As a trained neuroscientist, Dr. Reese has authored several scientific

and legal research papers in peer-reviewed journals. Dr. Reese is active in providing pro bono services in intellectual property for several entities in the Boston area and currently serves as co-chair of the American Bar Association’s Nanotech Committee.

利用相分離機制以磷灰石奈米粒子備製新型多孔複合材料

為了解決SILVER LINK的問題，作者曾于珊 這樣論述：

本研究嘗試由水/2,6-二甲基吡啶相分離系統組成之雙連續界面堵塞乳液凝膠( Bicontinuous Interfacially Jammed Emulsion Gels, Bijel )，結合化學改性的羥基磷灰石(HAp)奈米粒子網目製造一新型雙連續滲流軟材料。首先為了拓展奈米粒子的功能性，特別用氨丙基三乙氧基矽烷（APTS）修飾表面以得疏水HAp-APTS。這種化學修飾可做為染料連接劑，也能進一步被其他生物活性分子功能化。在控制溫度的情况下，觀察到隨相分離後界面出現，粒子聚集、形成網目能有效減緩兩相成長粗化。接著為了進一步了解粒子網目形成時「相分離動力學」與「相疇幾何」的複雜互動，紀錄該

Bijel系統在不同粒子參數(粒徑和濃度)下隨時間的相疇尺寸演變。最後藉由聚乙二醇二丙烯酸酯(PEGDA)的選擇性光固化，強化由HAp-APTS 網目形成的微米尺度Bijel 模板。即能在維持結構型態的前提下，為後續不同應用領域精準設計高比表面積且相疇尺寸可控制的多孔結構。